Across TCGA pan-cancer cohorts, KRTAP2-3 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated KRTAP2-3 data layer compared with 24 for mass-spec protein.
The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher KRTAP2-3 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated KRTAP2-3 expression acts as an unfavorable survival marker.
UCEC and ESCA are the cancer types where KRTAP2-3 Mutation most reproducibly stratifies survival.